AKRO Akero Therapeutics Inc

USD 26.82 -0.97 -3.490464
Icon

Akero Therapeutics Inc (AKRO) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 26.82

-0.97 (-3.49)%

USD 1.92B

0.89M

USD 44.14(+64.59%)

USD 36.00 (+34.23%)

Icon

AKRO

Akero Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 26.82
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.92B

USD 36.00 (+34.23%)

USD 26.82

Akero Therapeutics Inc (AKRO) Stock Forecast

Show ratings and price targets of :
USD 44.14
(+64.59%)

Based on the Akero Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for Akero Therapeutics Inc is USD 44.14 over the next 12 months. Akero Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Akero Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Akero Therapeutics Inc’s stock price was USD 26.82. Akero Therapeutics Inc’s stock price has changed by -0.96% over the past week, +12.45% over the past month and -37.83% over the last year.

No recent analyst target price found for Akero Therapeutics Inc
No recent average analyst rating found for Akero Therapeutics Inc

Company Overview Akero Therapeutics Inc

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects agains...Read More

https://www.akerotx.com

601 Gateway Boulevard, South San Francisco, CA, United States, 94080

58

December

USD

USA

Adjusted Closing Price for Akero Therapeutics Inc (AKRO)

Loading...

Unadjusted Closing Price for Akero Therapeutics Inc (AKRO)

Loading...

Share Trading Volume for Akero Therapeutics Inc Shares

Loading...

Compare Performance of Akero Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AKRO

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Akero Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.48 (+0.10%) USD126.85B 31.94 20.00

ETFs Containing AKRO

Symbol Name AKRO's Weight Expense Ratio Price(Change) Market Cap
SURI
Simplify Propel Opportuni.. 4.39 % 2.51 % -0.55 (-2.27%) USD0.12B

Frequently Asked Questions About Akero Therapeutics Inc (AKRO) Stock

Based on ratings from 5 analysts Akero Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on AKRO's stock to indicate if its a good dividend stock.

Based on targets from 5 analysts, the average taret price for AKRO is USD 44.14 over the next 12 months. The maximum analyst target price is USD 56 while the minimum anlayst target price is USD 30.

AKRO stock's Price/Earning ratio is 8.18. Our analysis grades AKRO stock's Price / Earning ratio at F. This means that AKRO stock's Price/Earning ratio is above 51% of the stocks in the Biotechnology sector in the NSD exchange. Based on this AKRO may be a overvalued for its sector.

The last closing price of AKRO's stock was USD 26.82.

The most recent market capitalization for AKRO is USD 1.92B.

Based on targets from 5 analysts, the average taret price for AKRO is projected at USD 44.14 over the next 12 months. This means that AKRO's stock price may go up by +64.59% over the next 12 months.

Following are ETFs with the highest allocation to Akero Therapeutics Inc's stock :

SURI

As per our most recent records Akero Therapeutics Inc has 58 Employees.

Akero Therapeutics Inc's registered address is 601 Gateway Boulevard, South San Francisco, CA, United States, 94080. You can get more information about it from Akero Therapeutics Inc's website at https://www.akerotx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...